NCT04879420View on ClinicalTrials.gov

Replication of the VERO Osteoporosis Trial in Healthcare Claims Data

CompletedOBSERVATIONAL
Enrollment

12,757

Participants

Timeline

Start Date

October 29, 2020

Primary Completion Date

June 11, 2021

Study Completion Date

June 11, 2021

Conditions
Osteoporosis
Interventions
DRUG

Teriparatide

Teriparatide dispensing claim is used as the reference group.

DRUG

Risedronate

Risedronate dispensing claim is used as the exposure group.

Trial Locations (1)

02120

Brigham and Women's Hospital, Boston

All Listed Sponsors
lead

Brigham and Women's Hospital

OTHER

NCT04879420 - Replication of the VERO Osteoporosis Trial in Healthcare Claims Data | Biotech Hunter | Biotech Hunter